JOURNAL ARTICLE

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Case Medical Research

Year: 2019 Journal:   Case Medical Research   Publisher: Case Journals
Keywords:
Daunorubicin Cytarabine Myeloid leukemia Medicine Leukemia Oncology Pharmacology Internal medicine

Metrics

0
Cited By
0.00
FWCI (Field Weighted Citation Impact)
0
Refs
0.34
Citation Normalized Percentile
Is in top 1%
Is in top 10%

Topics

Acute Myeloid Leukemia Research
Health Sciences →  Medicine →  Hematology
Chronic Myeloid Leukemia Treatments
Health Sciences →  Medicine →  Hematology
Histone Deacetylase Inhibitors Research
Life Sciences →  Biochemistry, Genetics and Molecular Biology →  Molecular Biology

Related Documents

JOURNAL ARTICLE

Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia

Aaron RonsonAriella TvitoJacob M. Rowe

Journal:   Expert Opinion on Orphan Drugs Year: 2016 Vol: 5 (4)Pages: 369-374
JOURNAL ARTICLE

Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia

Hannah AsghariJeffrey E. Lancet

Journal:   Leukemia & lymphoma/Leukemia and lymphoma Year: 2020 Vol: 61 (6)Pages: 1305-1312
© 2026 ScienceGate Book Chapters — All rights reserved.